HealthEquity, Inc.
NASDAQ:HQYMedical - Healthcare Information Services
-$0.54 today
- Market cap
- $8.05B
- Beta
- 0.21
- P/E (TTM)
- 31.4
- EPS (TTM)
- $2.73
Volume 1.29M
Average 0.98M
HQY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
HealthEquity, Inc.NASDAQ: HQY
Research & Development · Q2 FY2027 · quarter ended Jul 2026
Research & development growth accelerates
Q2 FY2027 research & development of $73.92M rose 14.1% year over year, ahead of the +10.7% change in trailing-twelve-month research & development. Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.
Context
- Research & development amounted to 20.0% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.1% holds above the trailing-twelve-month pace of +10.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 262.51M USD
- Year-over-year change
- +9.6%
- 4-year CAGR
- +13.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 262.51M | +9.6% |
| FY2025 | 2025-01-31 | 239.51M | +9.5% |
| FY2024 | 2024-01-31 | 218.81M | +13.2% |
| FY2023 | 2023-01-31 | 193.38M | +22.9% |
| FY2022 | 2022-01-31 | 157.36M | — |
Research & Development vs competitors
How HQY compares with its peers on the latest reported figures
- HQY's LTM Jul 2026 research & development of $277.96M is the highest of the 8 companies compared; the peer median is $63.14M.
- Its year-over-year change of +10.7% is the 3rd highest of 7, against a peer median of -0.5%.
- Research & development amounts to 20.4% of revenue for HQY, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $277.96M | +10.7% | +10.7% | 20.4% | |
| LTM Apr 2026 | $117.98M | -1.9% | +10.0% | 23.8% | |
| LTM Mar 2026 | $89.67M | +1.0% | -5.8% | 7.3% | |
| LTM Jun 2026 | $67.01M | +44.9% | +18.5% | 5.6% | |
| LTM Mar 2026 | $63.14M | -22.5% | -19.3% | 26.6% | |
| LTM Mar 2026 | $32.6M | -8.9% | +15.8% | 11.5% | |
| LTM Mar 2026 | $7.56M | +84.3% | +13.2% | 6.1% | |
CTEVClaritev Corporation | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding HQY) | $63.14M | -0.5% | +11.6% | 7.3% | |
Competitors are the stored peer set for HQY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 756.56M | 861.75M | 999.59M | 1.2B | 1.31B |
| Cost of Revenue | 415.64M | 466.24M | 469.71M | 507.19M | 400.31M |
| Gross Profit | 340.92M | 395.51M | 529.87M | 692.58M | 913.12M |
| Gross Margin | 45.1% | 45.9% | 53.0% | 57.7% | 69.5% |
| Research & Development | 157.36M | 193.38M | 218.81M | 239.51M | 262.51M |
| Selling, General & Admin | 142.98M | 164.48M | 182.93M | 223M | 328.15M |
| Operating Expenses | 300.35M | 357.85M | 401.74M | 462.51M | 590.66M |
| Depreciation & Amortization | 137.19M | 161.2M | 153.08M | 162.45M | 154.66M |
| EBITDA | 102.97M | 171.53M | 282.42M | 337.54M | 489.22M |
| EBITDA Margin | 13.6% | 19.9% | 28.3% | 28.1% | 37.2% |
| Operating Income | 40.57M | 37.65M | 128.13M | 230.07M | 322.46M |
| Operating Margin | 5.4% | 4.4% | 12.8% | 19.2% | 24.6% |
| Interest Income | 1.5M | 1.76M | 12.14M | 13.91M | 12.11M |
| Interest Expense | 36.57M | 48.42M | 55.46M | 60.63M | 57.13M |
| Other Income / Expenses | (107.31M) | (75.75M) | (53.09M) | (114.04M) | (45.02M) |
| Income Before Tax | (66.74M) | (38.1M) | 75.04M | 116.03M | 277.43M |
| Pre-Tax Margin | -8.8% | -4.4% | 7.5% | 9.7% | 21.1% |
| Income Tax Expense | (22.45M) | (11.95M) | 19.33M | 19.33M | 62.23M |
| Net Income | (44.29M) | (26.14M) | 55.71M | 96.7M | 215.2M |
| Net Margin | -5.9% | -3.0% | 5.6% | 8.1% | 16.4% |
| EPS (Basic) | (0.53) | (0.31) | 0.65 | 1.11 | 2.50 |
| EPS (Diluted) | (0.53) | (0.31) | 0.64 | 1.09 | 2.46 |
| Weighted Avg Shares | 83.13M | 84.44M | 85.56M | 86.87M | 86.13M |
| Weighted Avg Shares (Diluted) | 83.13M | 84.44M | 86.96M | 88.83M | 87.47M |
HealthEquity, Inc.
NASDAQ:HQY
Intrinsic Alpha fair value
Locked
Current Price
$97.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.